British Medical Journal at http://www.bmj.com/cgi/content/full/335/7630/1126
BMJ 2007;335:1126-1129 (1 December),
doi:10.1136/bmj.39400.549502.94
Analysis
Competition in a publicly funded healthcare system
Steffie Woolhandler,
associate professor of medicine, David
U Himmelstein, associate professor of medicine
Department
of Medicine, Cambridge Hospital, Harvard Medical School, Cambridge, MA, USA
Correspondence
to: D U Himmelstein, 1493 Cambridge Street, Cambridge, MA 02139, USA
Why would
anyone choose to emulate the US healthcare system? Costs per capita are about twice
the Organisation for Economic Cooperation and Development average. Forty
seven million people are completely uninsured. Many others with insurance face high out of pocket costs
that hinder care and bankrupt more than a million annually.1 Mortality
statistics lag behind those of most other wealthy countries, and even for the insured population, clinical outcomes and patient satisfaction are mediocre.2 3
This dismal
record arises, we contend, from health policies that emphasise market incentives. Even as the public share of
health spending in the US has risen to 60% (box) investor owned firms have eclipsed the public, professional, and
charitable bodies that previously managed the financing and delivery of care. The development and effect
of US policies that mix public funding and private management has wider relevance because politicians in
Europe and beyond are pushing
analogous schemes.
Tax financed health spending in U.S.:
- Official figures for 2005 peg government's share of total health expenditure
at 45.4%, but this excludes:
Tax subsidies for private insurance, which cost
the federal treasury $188.6bn (£92bn; 129bn)
in 2004 and predominantly benefit wealthy taxpayers
Government purchases of private health insurance
for public employees such as police officers and teachers. Government paid
private insurers $120.2bn for such coverage in 2005: 24.7% of the total spending by US employers for
private insurance
- Government's true share amounted to 9.7% of gross domestic product in 2005, 60.5% of total health spending or $4048 per capita (out of total expenditure of $6697)
- By contrast, government health spending in Canada and the UK was 6.9% and
7.2% of gross domestic profit respectively (or $2337 and $2371 per
capita)
- Government health spending per capita in the US exceeds total (public plus private)
per capita health spending in every country except Norway, Switzerland, and Luxembourg {and these countries
cover 100% of their citizens, and as a conssequence there is no private insurance companies paid for by employers and citizens
in those countries—jk.}
Failure of private contracting in Medicare
The combination
of tax funding and market oriented delivery is exemplified by the US Medicare programme, which has a budget more than double that of the entire NHS. Until 1965, many US employers offered private health cover, but elderly, poor, and disabled people were mostly uninsured and
forced to rely on threadbare government institutions or charity. In 1965, Congress established the Medicare
social insurance programme for elderly people. Private hospitals gained a vast new market, and investors soon
took note, launching for-profit chains that now account for 15% of US acute care hospitals. Similarly, for-profit
dialysis firms rushed in after the government made everyone with end stage renal disease eligible for
Medicare in 1972.
Until the
1970s, private insurers (mostly founded and controlled by doctors and hospitals) and Medicare exerted minimal oversight
of care and payment rates. But soaring costs prodded employers and government to assert more control. In
the private sector, managed care and health maintenance organisations (HMOs)—most of which were
controlled by investors rather than health providers and vigorously intervened in clinical care—rapidly gained
a foothold.
In the mid-1980s,
Medicare also began encouraging elderly people to enrol in private HMOs. Government paid the private plans
a fixed monthly premium for each person who switched from traditional (fee for service) Medicare, with the
HMO taking over responsibility for purchasing (or, rarely, providing) care. This arrangement was touted
as a means to bring market efficiency to the public programme and to broaden patients' choices.
Unfortunately, the first crop of Medicare HMOs yielded mainly scandal—for example, a major political donor whose plan enrolled thousands of aged patients in Florida (and collected tens
of millions of government dollars) but neglected to contract with doctors or hospitals to care for them. He fled
prosecution, eventually seeking refuge in Spain.4
Subsequently,
Medicare applied stricter regulations. The government set the HMOs' payment at 95% of the average monthly cost
of care for a patient in traditional Medicare, with the expectation of 5% savings through improved efficiency.
Patients who chose an HMO—attracted by free spectacles, lower copayments, and other benefits not
covered under traditional Medicare—were free to return to traditional Medicare whenever they wished.
HMOs recognised
an opportunity in the skewed distribution of health costs. Most patients use little care—indeed 22%
of elderly people cost Medicare nothing at all each year—while the fraction who are severely ill account
for the lion's share of expenditures. Astute HMO executives quickly realised
windfall profits through cherry picking—recruiting healthier than average older people who brought
hefty premiums but used little care—and returning sick patients, and their high medical bills,
to the traditional Medicare programme—disrupting care for millions.5
HMO marketing
departments devised selective recruitment schemes to attract healthy people. These included free fitness club
memberships, complimentary recruiting dinners at times and places inaccessible to frail elderly people, and
advertisements painted on the bottoms of swimming pools. HMOs used financial
incentives to encourage doctors to persuade sick patients to leave the HMO—for example, deducting
payments to specialists from the primary care doctor's own capitation payment. Hence, a general practitioner
could raise her income by advising patients needing hip replacement to leave the HMO, and even convince herself
that such advice might benefit patients by freeing them of HMO restrictions on the choice of surgeon and hospital.
HMOs concentrated
on ensuring convenient and attractive care for the modest needs of healthy (and profitable) older people.
Meanwhile, expensive, ill patients fared poorly. Stroke patients, those
needing home care, and others with chronic illnesses got skimpy care, had bad outcomes, and fled HMOs.5 6 7 8 And when all else failed and an HMO found itself saddled with too many unprofitably ill patients
in a particular county, executives simply closed up shop in that area and
returned the patients to traditional Medicare.
By the late
1990s, private HMOs' selective enrolment of healthy elderly people and removal of sick people had raised annual
Medicare costs by about $2bn.9 Yet despite this subsidy, HMOs couldn't effectively compete with traditional Medicare. The burden
of administrative costs—about 15% in the largest Medicare HMO10 compared with 3% in traditional Medicare—was too great to overcome. Many HMOs couldn't sustain
the extra benefits they had offered at the outset to attract members.
As enrolment
fell, HMOs lobbied hard for government rescue, and Congress upped their payments. Currently, Medicare pays private plans $77bn annually; the cost of caring for the eight million
Medicare members who have switched to HMOs is 12% above the cost of caring
for comparable patients in traditional Medicare.11
Medicare's
HMO contracting programme, originally touted as a market based strategy to improve the public programme's efficiency,
has evolved into a multibillion dollar subsidy
for private HMOs. Moreover, the massive financial power amassed by these
firms (largely at government expense) is a political roadblock to terminating this failed experiment.
Is private really better?
Other US experiments in using public
money to buy care from private firms have also disappointed. Costs for
the private insurance that government purchases for public employees have risen even faster than Medicare's.12 According to comprehensive meta-analyses, investor owned renal dialysis centres (funded almost
entirely by the special Medicare programme that covers everyone needing long term dialysis) have 9% higher mortality
than non-profit centres despite equivalent costs13; and investor owned hospitals—which receive most of their funding from public coffers—have 2% higher death rates and 19% higher costs than non-profit hospitals.14 15 Despite spending less on nurses and other clinical staff, investor owned
hospitals spend more on managers.16
If the failings
of private contracting in the US are underappreciated, so is the major success story of recent US health policy: the Veterans
Health Administration system. This network of hospitals and clinics owned and operated by government was long derided
as a US example of failed Soviet-style central planning. Yet it has recently emerged as a widely
recognised leader in quality improvement and information technology. At
present, the Veterans Health Administration offers more equitable care, of higher quality, at comparable
or lower cost than private sector alternatives.17
Costs of market forces
Health care's
shift from a public service to a business model has raised costs, partly by stimulating the growth of bureaucracy.
The proportion of health funds devoted to administration in the US
has risen 50% in the past 30 years and now stands at 31% of total health spending, nearly twice the proportion in Canada.18 Meanwhile, administration has been transmogrified from the servant
of medicine to its master, from a handful of support staff dedicated to facilitating patient care to a vast
army preoccupied with profitability.
Recent trends
elsewhere indicate that the US experience is not unique. The advent of internal markets sharply increased administrative
costs in the UK19 and New Zealand.20 The overheads of Canadian private insurers are 10 times higher than those of public provincial health
insurance programmes.18 In Australia, tax subsidies for private insurance have directed money through private firms, whose
overhead is 12% (versus 3.5% in the public programme)21; the private hospitals favoured by current policies are about 10% costlier than public ones.22 As Germany's insurance plans have adopted an increasingly business-like mode of operation, administrative
costs have soared, rising 63.3% between 1992 and 2003; meanwhile doctors complain about an avalanche of paperwork.23
Two factors
are at work. Firstly, fragmenting the funding stream, with multiple payers rather than a single government one,
necessarily adds complexity and redundancy. Secondly, high administrative costs are intrinsic to the
commercial mode (in medical care as elsewhere). Each party to a business transaction must maintain its
own detailed accounting records, not primarily for coordination but as evidence in case of disputes.24 Moreover, investors and regulators demand verification by independent auditors, generating yet
another set of records. Thus the commercial record replicates each clinical encounter in paper form before, during,
and after it takes place in the examining room. The sense of mutual obligation
and shared mission to which medicine once aspired becomes irrelevant, even a liability. Hence, the decision to unleash market forces is, among other things, a decision to divert healthcare dollars
to paperwork.
Market failure
Market theorists
argue that although competition increases administration, it should drive down total costs. Why hasn't practice
borne out this theory?
Investor owned healthcare firms are not cost minimisers but profit maximisers. Strategies that bolster profitability often worsen efficiency. US firms have found that raising
revenues by exploiting loopholes or lobbying politicians is more profitable than improving efficiency
or quality. Columbia/Hospital Corporation of America (HCA)—the biggest US private hospital operator—deliberately
submitted inflated bills and expenses to the government, structured business deals so that Medicare picked
up the cost of corporate expenses, and paid doctors in return for patient referrals.25 Tenet, the second largest hospital firm, has a long history of legal problems. In the 1980s (when the firm
was known as National Medical Enterprises) it gave doctors kickbacks to boost referrals and improperly
detained psychiatric patients in order to fill beds, resulting in legal settlements totalling nearly $700m.26 More recently, Tenet paid hundreds of millions of dollars in fines to resolve claims that it offered kickbacks
for referrals; claimed excessive sums from Medicare; and that its hospitals performed hundreds of unnecessary
cardiac procedures.27 28 29
For-profit
executives' incomes also drain money from care. When Columbia/HCA's chief executive officer resigned in the face
of fraud investigations into the company, he left with $324m in company stock. Tenet's chief executive exercised
stock options worth $111m shortly before resigning under pressure from investors in 2003. The head of
HealthSouth (the dominant provider of rehabilitation care, mostly paid for by Medicare) made $112m in 2002, the
year before his indictment for fraud (charges of which he was later acquitted) and four years before
his conviction on unrelated bribery charges.30
Even chief
executives of untainted firms have reaped enormous rewards. Former Harvard geriatrician John Rowe earned $225 000
a day (including Sundays and holidays) in his 65 months running Aetna health insurance company.31 Bill McGuire made $1.6bn after giving up pulmonary medicine to run UnitedHealthcare.32
While private
contracting has benefited executives and shareholders, it has increased costs and worsened quality because health
care cannot meet the fundamental requirements for a functioning market. It is fashionable to view patients
as consumers, but seriously ill people (who consume most care) cannot shop around, reduce demand when
suppliers raise prices, or accurately appraise quality. They necessarily rely on their doctor's advice on which
tests and treatments to "purchase."
Even for sophisticated
buyers like government, the "product" of health care is notoriously difficult to evaluate, particularly since doctors and hospitals create the data used to evaluate and reward them.
When Tenet hospitals did heart surgery on healthy patients, the surgical outcomes appeared first rate. Even for
honest firms, careful selection of lucrative patients and services is the key to success. Conversely, meeting
community needs often threatens profitability and hence institutional survival. In the past decade 425 emergency departments—magnets for both very sick and uninsured
patients unable to pay—have closed. Overcrowded US emergency departments turn away an ambulance once a minute, on average.33
Finally, a
real market would require multiple independent sellers, with free entry into the marketplace. Yet many hospitals
exercise virtual monopolies; half of Americans live in regions too sparsely populated to support real
medical competition.
What's driving privatisation?
Evidence
from the US
is remarkably consistent; public funding of private care yields poor results. In practice, public-private
competition means that private firms carve out the profitable niches, leaving a financially depleted public
sector responsible for the unprofitable patients and services. Based on
this experience, only a dunce could believe that market based reform will improve efficiency or effectiveness.
Why do politicians—who are anything but stupid—persist on this track?
Such reforms
offer a covert means to redistribute wealth and income in favour of the affluent and powerful. Privatisation
trades the relatively flat pay scales in government for the much steeper ones in private industry; the 15-fold
pay gradient between the highest and lowest paid workers in the US government gives way to the 2000:1
gradient at Aetna.
But even more
important, privatisation of publicly funded health systems uses the public treasury to create profit opportunities
for firms needing new markets. US private insurers used to focus on selling coverage to employer sponsored
groups and shunned elderly people as uninsurable. Now, with employers cutting health benefits, insurers
have turned to public treasuries for new revenues. And why stop at selling insurance? Why not tap into the
trillions spent annually on care in hospitals and doctors' offices?
Lessons for other countries
Market fundamentalists
conjure visions of efficient medical markets partnered with government oversight and funding to assure fairness
and universality. But regulation is overmatched. Incentives for optimal performance align imperfectly, at best,
with the real goals of care. Matrices intended to link payment to results instead reward entrepreneurs
skilled in clever circumvention. Their financial and political clout grows; those
who guilelessly pursue the arduous work of good patient care lose in the medical marketplace.
Health systems
in every nation need innovation and improvement. But remedies imported from commerce consistently yield inferior
care at inflated prices. Instead we prescribe adequate dosing of public funds; budgeting on a community-wide
scale to align investment with health priorities and stimulate cooperation among public health, primary,
and hospital care; encouragement of local innovation; explicit empowerment of patients and their families;
intensive audit for improvement, not reward or blame; a system based on trust and common purpose; and leadership
not by corporations but by "imaginative, inspired, capable and . . . joyous people, invited to use their
minds and their wills to cooperate in reinventing the system, itself . . . because of the meaning it
adds to the lives and the peace it offers in their souls."34
Hallmarks of market based reform:
- Market reforms aim to bring medicine into the realm of commerce, where commodities (homogeneous goods
or services) are bought and sold for profit
- The first stage of this process is to divide the medical enterprise into discreet, saleable units
(commodities), creating buyers and sellers—for example, separating responsibility for financing and
providing care or moving from global hospital budgets to fixed payment for a specific procedure
- Once medical commodities are defined, the sellers (medical providers) are forced to compete, giving
rise to financial winners and losers
- Because most medical commodities are heterogeneous (patients differ) providers can gain advantage
by market segmentation—for example, caring for a relatively healthy subgroup of patients with a particular
diagnosis
- Profitable providers attract investors and amass the financial (and political) power to expand their opportunities,
while unprofitable ones are driven from the market.
We thank Howard Waitzkin for useful comments.
Contributors and
sources: SW and DUH work as primary care doctors at an urban public hospital. Stimulated by their patients' difficulties
in obtaining care, they began research into the inadequacies of US healthcare. In 1986 they cofounded Physicians
for a National Health Program (www.PNHP.org), which advocates non-profit national health insurance in the US. Both authors participated equally in all aspects of this work, which draws on their research, experience
as clinicians in the US healthcare system, and extensive literature review. Both serve as guarantors.
Competing
interests: None declared.
Provenance and peer review: Not commissioned; externally peer
reviewed.
References
1. Himmelstein DU, Warren E, Thorne D, Woolhandler S. Illness and injury as contributors
to bankruptcy. Health Aff (Milwood) 2005;(suppl web exclusive):w5-63-w5-73.
2.
Davis K, Schoen C, Schoenbaum SC, Doty MM, Holmgren AL, Kriss JL, et al. Mirror, mirror on the
wall: an international update on the comparative performance of American health care. New York: Commonwealth Fund, 2007. www.commonwealthfund.org/publications/publications_show.htm?doc_id=482678
3.
Guyatt G, Devereaux P, Lexchin J,
Stone S, Yalnizyan A, Himmelstein D, Woolhandler S, et al. A systematic review of studies comparing health outcomes in Canada and the United States. Open Med 2007;1(1). www.openmedicine.ca/article/view/8/1
4.
Freedberg S. Miami mystery. Paid
to treat elderly, IMC moved in worlds of spying and politics. New York Times 1988 Aug 9:1.
5.
Morgan RO, Virnig BA, DeVito CA, Persily NA. The Medicare-HMO revolving door— the healthy
go in and the sick go out. N Engl J Med 1997;337:169-75.[Abstract/Free Full Text]
6.
Shaughnessy PW, Schlenker RE, Hittle
DF. Home healthcare outcomes under capitated and fee-for-service payment. Health Care Fin Rev 1994;16:187-222.[ISI][Medline]
7.
Retchin SM, Brown RS, Yeh SCJ, Chu
D, Moreno L. Outcomes of stroke patients in Medicare fee for service and managed care. JAMA 1997;278:119-24.[Abstract]
8.
Ware JE Jr, Bayliss MS, Rogers WH,
Kosinski M, Tarlov AR. Differences in 4-year health outcomes for elderly and poor, chronically ill patients treated in HMO
and fee-for-service systems. Results from the medical outcomes study. JAMA 1996;276:1039-47.[CrossRef][ISI][Medline]
9.
Risk selection and risk adjustment
in Medicare. In: Annual report to congress. Washington, DC: Physician Payment Review Commission, 1996.
10.
PacifiCare announces changes for
Secure Horizons Medicare HMO health plans in 2002. Medicare HMO Data Report, 2001. www.medicarehmo.com/mrepnr04b.htm
11.
Congressional Budget Office. Statement
of Peter R Orszag, director, on the Medicare advantage programme, June 28, 2007. www.cbo.gov/ftpdocs/82xx/doc8265/06-28-MedicareAdvantage.pdf
12.
Davis K, Cooper BS, Capasso R. The federal employee health benefits
program: a model for workers, not Medicare. New York: Commonwealth
Fund, 2003. www.cmwf.org/usr_doc/davis_fehbp_677.pdf
13.
Devereaux PJ, Schünemann HJ, Ravindran
N, Bhandari M, Garg AX, Choi PTL, et al . Comparison of mortality between private for-profit and private not-for-profit hemodialysis
centers: a systematic review and meta-analysis. JAMA 2002;288:2449-57.[Abstract/Free Full Text]
14.
Devereaux PJ, Choi PTL, Lacchetti
C, Weaver B, Schünemann HJ, Haines T, et al. A systematic review and meta-analysis of studies comparing mortality rates of
private for-profit and private not-for-profit hospitals. CMAJ 2002;166:1399-406.[Abstract/Free Full Text]
15.
Devereaux PJ, Heels-Ansdell D, Lacchetti
C, Haines T, Burns KEA, Cook DJ, et al. Payments for care at private for-profit and private not-for-profit hospitals: a systematic
review and meta-analysis. CMAJ 2004;170:1817-24.[Abstract/Free Full Text]
16.
Woolhandler S, Himmelstein DU. Costs
of care and administration at for-profit and other hospitals in the United States. N Engl J Med 1997;336:769-74.[Abstract/Free Full Text]
17.
Oliver A. The Veterans Health Administration:
an American success story? Milbank Q 2007;85:5-35.[CrossRef][ISI][Medline]
18.
Woolhandler S, Campbell T, Himmelstein
DU. Costs of health care administration in the United States and Canada.
N Engl J Med 2003;349:768-75.[Abstract/Free Full Text]
19.
Health Policy Network of the NHS
Consultants' Association, NHS Support Federation. In practice: The NHS market in the United Kingdom. J Public Health Policy 1995;16:452-91.[CrossRef][ISI][Medline]
20.
Coney S. Relentless unraveling of
New Zealand's health-care system. Lancet 1996;347:1825.[ISI][Medline]
21.
Willcox S. Promoting private health
insurance in Australia: Do Australia's latest health insurance reforms represent a
policy in search of evidence? Health Affairs 2001;20(3):152-61.[Abstract/Free Full Text]
22.
Duckett SJ, Jackson TJ. The new health
insurance rebate: An inefficient way of assisting public hospitals. Med J Australia 2000;172:439-42.[Medline]
23.
Hyde R. An end to Germany's bureaucratic nightmare? Lancet 2006;367:1717-8.[CrossRef][ISI][Medline]
24.
Braverman H. Labor and monopoly capital:
the degradation of work in the twentieth century. New York:
Monthly Review Press, 1974.
25.
Department of Justice. Largest health
care fraud case in US history settled: HCA investigation nets record total of $1.7
billion. Press release, 26 June, 2003. www.usdoj.gov/opa/pr/2003/June/03_civ_386.htm
26.
Eichenwald K. $100 million settlement
seen in Tenet suits. New York Times 1997 Jul 30:D1.
27.
Department of Justice. Tenet Healthcare
Corporation to pay US more than $900 million to resolve False Claims Act allegations. Press release, 29 June, 2006. www.usdoj.gov/opa/pr/2006/June/06_civ_406.html
28.
Eichenwald K. How one hospital benefited
from questionable surgery. New York Times 2003 Aug 12.
29.
Eichenwald K. Tenet Healthcare paying
$54 million in fraud settlement. New York Times 2003 Aug 7.
30.
Reeves J. The Scrushy case: Health
South founder begins 7-year sentence. Houston Chronicle
2007 Jun 30.
31.
Dash E. Executive pay: a special
report. Off to the races again, leaving many behind. New York Times 2006:Apr 9(section 3):1-9.
32.
Anders G. As patients, doctors feel
pinch, insurer's CEO is worth a billion. Wall Street Journal 2006 Apr 18:A1.
33.
Committee on the Future of Emergency
Care in the United
States Health
System. Hospital-based emergency care: at the breaking point. Washington, DC: National Academies Press, 2006.
34.
Berwick DM. Improvement, trust, and
the health care workforce. Qual Saf Health Care 2003;12:2-6.[Free Full Text]
Related Articles
We need to be more pragmatic
Adam Paul Fitzpatrick
BMJ 2008 336: 8-9. [Extract] [Full Text]
The market has failed
Fiona Godlee
BMJ 2007 335: 0. [Extract] [Full Text]